<DOC>
	<DOC>NCT00423332</DOC>
	<brief_summary>Cediranib is being tested to assess its effectiveness on the growth of kidney cancer tumours and also how well it is tolerated.</brief_summary>
	<brief_title>Cediranib (AZD2171, RECENTINâ„¢) in Metastatic or Recurrent Renal Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Renal Cell</mesh_term>
	<mesh_term>Cediranib</mesh_term>
	<criteria>Confirmation of metastatic or recurrent renal cell carcinoma Certain types of previous anticancer therapy for Renal Cell Carcinoma Patients with type I insulindependent diabetes or poorlycontrolled type II insulinindependent diabetes Patients with a history of poorly controlled high blood pressure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>cancer</keyword>
	<keyword>tumour</keyword>
	<keyword>advanced cancer</keyword>
	<keyword>Metastatic renal cell carcinoma</keyword>
	<keyword>kidney cancer</keyword>
	<keyword>RECENTIN</keyword>
</DOC>